Drugs and patents in ATC class N05AN

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ESKALITH	lithium carbonate
LITHIUM CARBONATE	lithium carbonate
LITHONATE	lithium carbonate
ESKALITH CR	lithium carbonate
>Tradename	>Generic Name

Last updated: June 19, 2026

Executive summary

ATC N05AN (Lithium) is a generics-dense segment with long-established actives (lithium carbonate and lithium salts such as lithium citrate and lithium aspartate). The core competitive pressure is typically off-patent, with market outcomes driven by formulation, dose forms (IR vs ER), labeling, distribution contracts, and safety-driven substitution frictions rather than brand-exclusive innovation.
The patent landscape is usually dominated by legacy composition, method, and formulation patents tied to specific salts, dose strengths, and release profiles. Where exclusivity persists, it is more often tied to specific FDA approvals and product-specific patents than to broad class-wide coverage.
For new entrants and challengers, the main risk is not “biosimilar” exposure but paragraph IV exposure against remaining Orange Book-listed patents for particular lithium products, especially ER formulations and branded prodrugs/specific salts. Patent life and exclusivity windows largely determine the timing of generic substitution in each dosage form.

What patents protect lithium (ATC N05AN) drugs like lithium carbonate and lithium citrate?

ATC N05AN covers lithium products used primarily for mood stabilization in bipolar disorder. Patent protection, where it exists, tends to be product-specific and dosage-form specific, not class-wide.

Which lithium actives fall under N05AN and what does that mean for patent scope?

Typical N05AN lithium actives include:

Lithium carbonate (most common)
Lithium citrate
Lithium salts used in formulations (varies by jurisdiction and brand)

Patent scope usually divides into:

Composition of matter (salt selection, hydrates, polymorphs)
Formulation (IR/ER matrix, coatings, particle engineering)
Methods of use (dose regimens, monitoring protocols)
Manufacturing processes (granulation, controlled release manufacturing)

In a market with long-established actives, remaining patents are often narrower, covering a specific formulation technology or a specific approved product.

How many patents cover lithium in the Orange Book for a given dosage form?

Coverage is typically fragmented by:

Brand product (different marketing authorization holders)
Strength
Release profile (IR vs ER)
Salt form (carbonate vs citrate)

The number of Orange Book-listed patents varies by product, but the segment is structurally consistent with a “thin-to-moderate” live-patent estate per product. The most litigated patents, where litigation occurs, tend to be formulation and method-of-use rather than broad composition-of-matter.

When does lithium lose exclusivity and what are the likely generic launch windows?

Generic launch timing for lithium products depends on:

Patent expiration for Orange Book-listed patents
Pediatric exclusivity windows (if granted)
Regulatory exclusivities tied to supplements or new formulations (rare for legacy lithium actives)
Market exclusivity under Hatch-Waxman for specific product approvals

How to read exclusivity timing for lithium products

For each branded lithium product, the relevant “do-not-launch-before” date is the earliest of:

Patent expiration of the latest Orange Book-listed patent that is still unexpired for the FDA-approved active ingredient, dosage form, and strength
Any pediatric exclusivity extension (6 months) triggered by qualifying data for that NDA/ANDA

What does the timeline usually look like in N05AN?

Given historical development, many lithium formulations are already post-expiration. Where exclusivity still matters, it usually concerns:

A newer ER or reformulated brand product
A specific approved salt form or engineered release technology

In practice, the generic “switch” tends to occur in waves:

After key patents expire for a given branded product
After settlements allow earlier launch for authorized generics or first-filer agreements
After payer and pharmacy formulary changes enable substitution

What is the Orange Book status of lithium products (and how does it drive paragraph IV risk)?

Orange Book status controls the paragraph IV pathway because ANDA applicants certify patent status (Paragraph I, II, III, IV).

What typically appears in the Orange Book for lithium products

Orange Book listings for lithium generally include:

Multiple patents tied to one branded lithium product NDA
Patents across categories: composition, formulation, and method-of-use
Separate patents for different release profiles within the same active ingredient segment

How paragraph IV challenges change the market dynamics

A successful paragraph IV challenge can trigger:

“First generic” launch advantages (if it is the earliest eligible filer)
Increased volume share capture quickly once coverage is cleared
A settlement that sets an agreed launch date (often earlier than the last patent expiry for that product)

For investors and litigators, paragraph IV challenges create the highest signal because they correlate with:

Remaining live patents
Litigation readiness and competitive intent
Likelihood of negotiated market entry windows

Which companies are challenging lithium patents and where does litigation concentrate?

Litigation in N05AN is typically localized to:

Branded ER or reformulated lithium products with late-expiring formulation/method patents
Specific strengths where formulation patents are strongest

Where settlement agreements typically land

Settlements in generic lithium cases often:

Set a defined entry date tied to the last-to-expire relevant patent
Permit launch of specific ANDA strengths or require certain labeling carve-outs
Include licensing terms where the brand grants an authorized generic, sometimes in exchange for dismissal

In market terms, settlements shift entry from “unknown contested” to “predictable scheduled,” lowering uncertainty for wholesalers and pharmacy chains.

How do lithium formulations (IR vs ER, salt form, and dosing) affect patent coverage?

Formulation is a key determinant of both IP barriers and market outcomes.

What formulation patents tend to cover

Typical formulation patent themes for lithium include:

Controlled-release architectures (matrices, coatings)
Drug particle engineering (size distributions and dissolution behavior)
Tablet technologies affecting GI transit and release rate
Stability and manufacturing process controls tied to release and bioavailability

Why IR/ER matters commercially

ER products can be favored by adherence and tolerability profiles.
IR substitution can be constrained by prescriber preferences and patient history.
Payers may segment reimbursement by release profile even when active ingredient equivalence exists.

Patent coverage that differentiates ER from IR can therefore delay generic substitution even after some composition patents expire.

What method-of-use patents exist for lithium and how do they block generics?

Method-of-use patents do not stop FDA approval on their own, but they affect:

ANDA labeling design
Patent carve-outs and litigation risk
Settlement terms that restrict generic label claims until a certain date

Typical method-of-use patent themes

Lithium method patents often focus on:

Dosing regimens
Monitoring schedules for serum lithium levels
Patient selection criteria (rare but occurs)
Concomitant therapy adjustments

These patents can create “labeling-block” dynamics where FDA approval proceeds but commercialization is delayed due to litigation or negotiated scope limitations.

Does lithium have biosimilar risk or only generic small-molecule risk?

Lithium products are small-molecule drugs. Biosimilar pathways do not apply.

Market implication

The primary entry threat is ANDA generic competition.
The primary litigation pathway is Hatch-Waxman paragraph IV against Orange Book-listed patents.

How does lithium compare with other N05AN agents in patent and market structure?

N05AN is a therapeutic class centered on lithium. Compared with other psychiatric categories:

Patent lifecycles for lithium are largely mature
Competitive dynamics hinge on cost, supply reliability, and formulation-specific switches
Safety and monitoring requirements influence substitution behavior more than IP barriers once patents expire

What generic entry risks exist for lithium products and how do they vary by dosage form?

Risks for ANDA applicants typically include:

Remaining unexpired formulation or method patents (Orange Book)
Manufacturing compliance risks tied to release profile replication
Settlement-driven design constraints (strength or label limitations)

Strength-level risk

Lithium products can have multiple strengths tied to different device formats and release profiles. Generic applicants often evaluate:

Whether the relevant patent claims map cleanly to a particular strength
Whether there are carve-outs in settlement agreements

Which manufacturing and IP barriers can delay lithium generic substitution?

Even when patents expire, operational barriers can slow adoption:

Formulation reproduction complexity for ER release
Supply chain reliability for lithium salts
Quality system validation for dissolution profiles and stability

From an IP perspective, the main barriers remain:

Remaining Orange Book formulation patents
Remaining method-of-use patents shaping labeling

Revenue exposure: how much of the lithium market is tied to remaining branded exclusivity?

In a mature generic segment, branded revenue exposure depends on:

Whether a branded ER product still has live patents
Whether payer formularies continue to cover branded products at parity
Whether branded product has distribution or patient support advantages

Market outcomes typically show:

Rapid volume decline following generic launches
Brand retention in narrower segments where release profile or monitoring outcomes are emphasized by prescribers

Key patent estate patterns in N05AN lithium: what tends to be strong vs weak?

Stronger patent types (when still live)

Formulation/release patents that map directly to ER product architecture
Method-of-use patents with specific dosing/monitoring claims
Process patents that are harder to design around without triggering infringement risk

Weaker patent types (post-maturity)

Broad early composition patents already expired
Overlapping patents with narrow claim scope that are easy to circumvent via different formulation design (when feasible)

Key Takeaways

N05AN lithium is a mature, generics-dominant market where patent impact is product-specific, typically tied to ER/formulation and any remaining method-of-use claims listed in the Orange Book for particular branded products.
Exclusivity and generic launch timing are driven by the last-to-expire Orange Book patents for each NDA and dosage form, plus any pediatric extensions where applicable.
The competitive battleground is usually paragraph IV litigation for a specific branded lithium product rather than broad class-wide IP.

FAQs

How do Paragraph IV certifications work for lithium ANDAs when multiple Orange Book patents are listed?
Do lithium ER generics face higher patent and FDA risk than IR generics?
What claim elements in formulation patents most often determine infringement outcomes for controlled-release lithium tablets?
Can method-of-use patents delay lithium generic commercialization without preventing FDA approval?
How do settlements typically structure launch dates for lithium generics across strengths?

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-19)

Drugs in ATC Class N05AN

Drugs in ATC Class: N05AN - Lithium

Market Dynamics and Patent Landscape for ATC Class N05AN (Lithium): Exclusivity Timelines, Orange Book Status, and Generic/Biosimilar Risk